Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy
JCO Precision Oncology · 2024
DOI: 10.1200/po.24.00289 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Rani Bansal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Duke Cancer Institute, Duke University Hospital, Durham, NC. Hauptthemen laut MEDLINE: Phyllodes Tumor, Breast Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Malignant phyllodes tumors (MPTs) are rare fibroepithelial tumors of the breast with aggressive biologic behavior and high recurrence rates. Surgery remains the primary treatment modality for these tumors; however, initial investigations suggest a potential for targeted therapies in managing this disease. Therefore, we aimed to assess the molecular landscape of MPTs to reveal possible treatment opportunities. METHODS MPTs (n = 57) from primary and metastatic sites underwent genomic sequencing (592-gene panel or whole exome), whole-transcriptome sequencing, and immunohistochemistry (PD-L1, human epidermal growth factor receptor 2 [HER2]) at Caris Life Sciences (Phoenix, AZ). Immune cell fractions in the tumor microenvironment were estimated using quanTIseq. Mann-Whitney U , chi-square, and Fisher’s exact tests were used to determine significance ( P < .05). RESULTS MPTs had low ERBB2 expression, comparable with the HER2-negative subset of a large cohort of breast adenocarcinoma samples (N = 9,926). Frequent alterations included TERT promoter; MED12 , TP53 , and NF1 mutations; and less frequently EGFR , PIK3CA , and BRAF . Differences in mutation prevalences were observed between primary sites, lung metastases, and nonlung metastases. One MPT specimen harbored a pathogenic TPM4:NTRK1 fusion, and treatment with larotrectinib for over 16 months suggested a clinical response to therapy. PD-L1+ status was observed in 15.2% of MPTs overall, with similar prevalence in primary sites and lung metastases. B cells, M2 macrophages, neutrophils, and natural killer cells had the highest median cell fractions in MPTs. CONCLUSION Considering the occurrence of several actionable alterations including a TPM4:NTRK1 fusion reported herein, these results support the use of next-generation sequencing (NGS) including RNA analysis for fusion detection to identify such alterations in patients with MPTs. These findings highlight the importance of comprehensive NGS in MPT research to uncover potential targeted treatment options for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Duke Cancer Institute, Duke University Hospital, Durham, NC.
- Caris Life Sciences, Phoenix, AZ.
- Levine Cancer Institute, Atrium Health, Charlotte, NC.
- Emory University, Atlanta, GA.
- Legorreta Cancer Center at Brown University, Providence, RI.
- Lifespan Cancer Institute, Providence, RI.
ORCID-Profile: Rani Bansal, Antoinette R Tan, Jennifer R Ribeiro, Matthew J Oberley, Stephanie L Graff, George W Sledge, Juneko E Grilley-Olson, Sarah L Sammons, Laura H Rosenberger
Zitieren
APA
Bansal, R., Adeyelu, T., Elliott, A., Tan, A. R., Ribeiro, J. R., Meisel, J., Oberley, M. J., Graff, S. L., Sledge, G. W., Grilley-Olson, J. E., Sammons, S. L., & Rosenberger, L. H. (2024). Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy. JCO Precision Oncology. https://doi.org/10.1200/po.24.00289
Vancouver
Bansal R, Adeyelu T, Elliott A, Tan AR, Ribeiro JR, Meisel J, et al. Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy. JCO Precision Oncology. 2024. doi:10.1200/po.24.00289
BibTeX
@article{Bansal2024,
author = {Bansal, Rani and Adeyelu, Tolulope and Elliott, Andrew and Tan, Antoinette R and Ribeiro, Jennifer R and Meisel, Jane and Oberley, Matthew J and Graff, Stephanie L and Sledge, George W and Grilley-Olson, Juneko E and Sammons, Sarah L and Rosenberger, Laura H},
title = {Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.24.00289}
}
EUVIMED